With the most potent weight-loss shot and a pipeline of 11 experimental treatments, including what is widely expected to be the first approved small molecule GLP-1 pill, Eli Lilly stands to be ...
Eli Lilly’s two weight loss drugs have become blockbusters, bringing in more than $1 billion in annual revenue. Demand is growing in this market, but so is competition. These players, as well as ...
16d
Eli Lilly is on track to become the first trillion-dollar pharma company, fueled by FDA-approved weight loss drugs. With a ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...
Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...
The US Food and Drug Administration confirmed Thursday that Eli Lilly (LLY) has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the ...
Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...
New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and Eli Lilly LLY in a potential $200 billion total GLP-1 market, which we expect will see 68% ...
The Food and Drug Administration signed off on a new eczema drug from Eli Lilly. Is Eli Lilly stock a buy right now? Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback